Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes-Reference-Cited by-同舟云学术

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes

Published:2009-05 Issue:5 Volume:15 Page:610-617
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Besien Koen Van,Kunavakkam Rangesh,Rondon Gaby,De Lima Marcos,Artz Andrew,Oran Betul,Giralt Sergio

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference53 articles.

2. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning;Shimoni;Leukemia,2005

3. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years;Wong;Blood,2003

4. Non-ablative versus reduced intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome. Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation;de Lima;Blood,2004

5. Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for myeloablative conditioning [abstract];Giralt;Blood,1997

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention;Blood Advances;2024-08-15

2. The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation;Expert Review of Hematology;2023-11-06

3. Acute graft-versus-host disease;Nature Reviews Disease Primers;2023-06-08

4. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT;Blood Advances;2023-01-25

5. Immunotherapy with CD25/CD71-allodepleted T cells to improve T-cell reconstitution after matched unrelated donor hematopoietic stem cell transplant: a randomized trial;Cytotherapy;2023-01